Effect of simvastatin in the autonomic system is dependent on the increased gain/sensitivity of the baroreceptors by Moreira, Edson D. et al.
  Universidade de São Paulo
 
2013-08
 
Effect of simvastatin in the autonomic system
is dependent on the increased gain/sensitivity
of the baroreceptors
 
 
Physiological Reports, Malden, v.1, n.3, p.e00045, 2013
http://www.producao.usp.br/handle/BDPI/44316
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Anatomia - ICB/BMA Artigos e Materiais de Revistas Científicas - ICB/BMA
ORIGINAL RESEARCH
Effect of simvastatin in the autonomic system is dependent
on the increased gain/sensitivity of the baroreceptors
Edson D. Moreira1, Cristiano T. Mostarda2, Ivana C. Moraes-Silva1, Janaina B. Ferreira1, Fernando
dos Santos1, Silvia Lacchini3, Katia De Angelis4, Bruno Rodrigues5 & Maria Claudia Irigoyen1
1 Experimental Hypertension Laboratory, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil
2 Hospital Universitario Materno Infantil, Federal University of Maranh~ao (UFMA), Sao Luiz-Maranh~ao, Brazil
3 Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
4 Translational Physiology Laboratory, Nove de Julho University (UNINOVE), Sao Paulo, Brazil
5 Human Movement Laboratory, Sao Judas Tadeu University (USJT), Sao Paulo, Brazil
Keywords
Baroreceptor function, baroreflex sensitivity,
Hypertension, statins, sympathetic
modulation.
Correspondence
Maria Claudia Irigoyen, Experimental
Hypertension Laboratory, Heart Institute
(InCor), University of S~ao Paulo Medical
School (FMUSP), Av. Dr. Eneas de Carvalho
Aguiar, 44 – Bloco I – subsolo, S~ao Paulo, SP,
Brazil 05403-900.
Tel: 55-11-26615006
Fax: 55-11-26615327
E-mail: hipirigoyen@incor.usp.br
Funding Information
This study was supported by Fundac~ao de
Amparo a Pesquisa do Estado de S~ao Paulo
(FAPESP- 01/00,009-0; 2012/20,141-5),
Conselho Nacional de Pesquisa e
Desenvolvimento (CNPq), and Fundacao E.J.
Zerbini. K. D. A. and M. C. I. had a financial
support from CNPq-BPQ.
Received: 24 April 2013; Revised: 3 July
2013; Accepted: 4 July 2013
doi: 10.1002/phy2.45
Physiol Rep, 1 (3), 2013, e00045, doi:
10.1002/phy2.45
Abstract
A number of mechanisms have been proposed to explain the pleiotropic effect
of statin therapy to reduce sympathetic outflow in cardiovascular disease. We
tested the hypothesis that statin treatment could improve baroreflex gain-sensi-
tivity triggered by morphological adaptations in the mechanoreceptor site, thus
reducing sympathetic activity, regardless of arterial pressure (AP) level reduc-
tion. Male spontaneously hypertensive rats (SHR) were divided into control
(SHR, n = 8) and SHR-simvastatin (5 mg/kg/day, for 7 days) (SHR-S, n = 8).
After treatment, AP, baroreflex sensitivity (BRS) in response to AP-induced
changes, aortic depressor nerve activity, and spectral analyses of pulse interval
(PI) and AP variabilities were performed. Internal and external carotids were
prepared for morphoquantitative evaluation. Although AP was similar between
groups, sympathetic modulation, represented by the low frequency band of PI
(SHR: 6.84  3.19 vs. SHR-S: 2.41  0.96 msec2) and from systolic AP vari-
ability (SHR: 3.95  0.36 vs. SHR-S: 2.86  0.18 mmHg2), were reduced in
treated animals. In parallel, simvastatin induced an increase of 26% and 21% in
the number of elastic lamellae as well as a decrease of 9% and 25% in the
carotid thickness in both, external and internal carotid, respectively. More-
over, improved baroreceptor function (SHR: 0.78  0.03 vs. SHR-S:
1.06  0.04% mv/mmHg) was observed in addition to a 115% increase in aor-
tic depressor nerve activity in SHR-S rats. Therefore, our data suggest that the
reduction of sympathetic outflow in hypertension by simvastatin treatment may
be triggered by structural changes in the carotid arteries and increased BRS in
response to an improvement of the baroreceptors discharge and consequently
of the afferent pathway of the baroreflex arch.
Introduction
Hypertension, a major risk factor in the development of
cardiovascular disease, is often associated with alterations
in blood pressure control mechanisms. It is well known
that chronic elevation of blood pressure alters barorecep-
tor sensitivity, and induces end organ damage (Andresen
and Yang 1989; Grassi 2010). In addition, several studies
have suggested that a depressed baroreflex activity is a
strong predictor of cardiac mortality (La Rovere and
Bigger 1998; La Rovere et al. 2013).
Classically, HMG-CoA reductase inhibitors, or statins,
are used to manage dyslipidemia, but they also present
beneficial effects beyond lipid lowering; for instance,
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blood pressure reduction (Sposito et al. 1999; Wassmann
et al. 2001; Borghi et al. 2002) in central and peripheral
sympathetic activity (Gomes et al. 2010; Deo et al. 2012),
and improvement in antiinflammatory responses (Bu
et al. 2011). Furthermore, in hypertensive Dahl salt-sensi-
tive rats, treatment with atorvastatin prevented vascular
endothelial nitric oxide synthase (eNOS) downregulation
and inhibited oxidative stress in the aorta, contributing to
the protection against end organ injury in salt-sensitive
hypertension (Zhou et al. 2004).
One of the most remarkable pleiotropic effects of sta-
tins may be the increase in nitric oxide synthase (NOS)
bioactivity, which in turn improves endothelial function
(O’Driscoll et al. 1997). Indeed, Rossoni et al. (2011)
have demonstrated that simvastatin acutely increases NO
phosphorylation in isolated resistance arteries, even in
control rats. This statin-related increase in NO bioavail-
ability statins also positively impacts the autonomic ner-
vous system function and baroreflex control of blood
pressure by a central nervous system-induced mechanism
(Gao et al. 2005; Kishi and Hirooka 2010). Previous
attempts to study the mechanisms behind simvastatin-
induced cardiac autonomic control improvement in heart
failure have shown that not only NO but also AT1 recep-
tors and nicotinamide adenine dinucleotide phosphate
oxidase are modulated and could account for the reduc-
tion in peripheral sympathetic activity (Gao et al. 2005).
Nevertheless, other peripheral candidate mechanisms
may be behind the improved control of blood pressure
observed in statin-treated patients. Therefore, we carried
out the present study to investigate whether simvastatin
treatment, which does not alter resting blood pressure lev-
els, is able to improve autonomic control of the heart and
vessels, as well as the baroreflex sensitivity (BRS) and func-
tion in hypertensive rats. We tested whether short-term sta-
tin treatment could lead to an improvement in baroreflex
gain triggered by morphological adaptations in the mecha-
noreceptor site and to a reduction in sympathetic activity,
regardless of any reduction in arterial pressure (AP) levels.
Methods
Animals
Sixteen male spontaneously hypertensive rats (SHR) (Fed-
eral University of Sao Paulo, Brazil), weighing from 200
to 250 g, were fed standard laboratory chow and water ad
libitum in a temperature-controlled room (22°C) with a
dark–light cycle of 12/12 h. All procedures were per-
formed in accordance with the Guidelines for the Care
and Use of Laboratory Animals, published by the National
Institutes of Health (NIH Publication No. 85-23, Revised
1996).
The rats were randomly distributed in two groups: SHR
(n = 8) and SHR treated with simvastatin (SHR-S)
(n = 8). Simvastatin (lot no SIM0400916-1 Galena, Camp-
inas, SP, Brazil) was dissolved in distilled water and given
by gavage during 7 days at a dose of 5 mg/kg/day. A previ-
ous study of our laboratory showed that this treatment reg-
imen do not significantly alter AP (data not showed).
Cardiovascular assessments
After the 7 days of treatment, two catheters filled with
0.06 mL saline were implanted in anesthetized rats
(80 mg/kg ketamine and 12 mg/kg xylazine) into the fem-
oral artery and vein (PE-10) for direct measurements of
AP and drug administration, respectively. Rats were stud-
ied 48 h after catheter placement; the rats were conscious
and allowed to move freely in the cage during the experi-
ments. The arterial cannula was connected to a strain-
gauge transducer (Blood Pressure XDCR, Kent© Scientific,
Litchfield, CT), and AP signals were recorded over a
20-min period by a microcomputer equipped with an ana-
log-to-digital converter board (using a Dataq Instruments
DI-720, 16-bit measurement resolution, 2 kHz sampling
rate, Springfield, OH). The software used for the acquisi-
tion was WINDAQ/PRO (Dataq Instruments, Springfield,
OH) waveform recording software. The recorded data
were analyzed on a beat-to-beat basis to quantify changes
in mean AP (MAP) and heart rate (HR).
In order to evaluate BRS, increasing doses of phenyl-
ephrine (0.25–1 lg/animal) and sodium nitroprusside
(0.5–2 lg/animal) were given as sequential bolus injec-
tions (0.1 mL) to produce AP responses ranging from 5
to 40 mmHg. A 3- to 5-min interval between doses was
necessary for AP to return to its baseline. Peak increases
or decreases in MAP after phenylephrine or sodium nitro-
prusside injection and the corresponding peak reflex
changes in HR were recorded for each dose of the drug.
BRS was evaluated by a mean index through a relationship
between changes in HR and in MAP, allowing separate
analysis of reflex bradycardia and tachycardia. The mean
index was expressed as bpm/mmHg (Farah et al. 1999).
Power spectral analysis
Spectral analysis of systolic AP (SAP) and pulse interval
(PI) were analyzed by autoregressive parametric spectral
method that automatically provide the number, center fre-
quency, and power of each oscillatory component. In brief,
a derivative-threshold algorithm provides the continuous
series PI (tachogram). From the SAP signal, the systogram
was created through the beat-to-beat systolic pressure. The
low frequencies (0.20–0.75 Hz) and high frequencies
(0.75–3.00 Hz) spectral components of PI and SAP were
2013 | Vol. 1 | Iss. 3 | e00045
Page 2
ª 2013 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
Simvastatin and Autonomic Nervous System E. D. Moreira et al.
expressed in absolute (ms², mmHg²) and in normalized
units (nu). The normalized units were obtained by calculat-
ing the power of low frequency (LF) and high frequency
(HF) correlating each to the total power, after subtracting
the power of the very low-frequency component (frequen-
cies of <0.2 Hz) (Soares et al. 2004).
Baroreceptor gain-sensitivity
The recording of the whole-nerve activity of the aortic
depressor nerve for aortic baroreceptor gain-sensitivity
evaluation was performed in anesthetized rats (sodium
pentobarbital, 30 mg/kg, i.p.) after 7 days of Simvastatin
treatment. Platinum bipolar electrodes (0.050 mm thick-
ness) with high-input impedance and small interelectrode
distance (1.2 mm between electrodes) were fixed at the
aortic depressor nerve, protected with a lightweight sili-
con impression material (Wacker Sil-Gel 604, Wacker-
Chemie, Munich, Germany), and continuously displayed
on an oscilloscope (5115 Tektronix Storage Oscilloscope,
Heerenveen, Netherlands).
The nerve action potentials were amplified (5–10 kHz
of gain; AN502 Differential Amplifier, Tektronix, OR),
filtered (bandwidth 0.1–3.0 kHz), and the full-wave activ-
ity were rectified, and further integrated by using the
pulse pressure as a trigger on a beat-to-beat basis. Both
aortic depressor nerve activity and AP were sampled at
10 kHz (DataQ Instruments, Inc., OH).
The aortic baroreceptor gain-sensitivity was evaluated
by two different protocols: during spontaneous and
induced changes of blood pressure (phenylephrine,
5 lg/kg and sodium nitroprusside, 5 lg/kg) by drug
infusion via the femoral vein. To permit comparison of
the baroreceptor discharges in different rats, nerve
activity was normalized as a percentage of the maximal
discharge at higher AP levels in the control animals
(expressed as % mmHg1), as previously described by
our group (Brum et al. 2000; Soares et al. 2004;
Rondon et al. 2006).
Two approaches were used to analyze the AP-nerve
activity relationship. The baroreceptor gain-sensitivity was
evaluated by linear regression and by the full range of AP
variations. The full SAP range for baroreceptor activation,
defined by the difference between SPth (systolic pressure
at which the baroreceptors initiated firing) and SPst (the
pressure level at which continuous baroreceptor discharge
was achieved during a rapid increase in AP) was used to
calculate the index of sensitivity expressed as%.mv/mm/
Hg. Moreover, baroreceptor gain-sensitivity was evaluated
by fitting a linear regression describing the relationship of
the mean changes in the nerve discharge obtained during
SAP variations ranges of 2 mmHg. The average slope of
the liner regression was considered as an index of barore-
ceptor gain-sensitivity (Brum et al. 2000; Rondon et al.
2006).
Carotid morphometric evaluations
To evaluate carotid histology, hearts were arrested in dias-
tole by perfusion with a NaCl (0.9%) plus 14 mmol/L KCl
solution, followed by buffered formalin (4%) for tissue fix-
ation. The neck was harvested to expose the neurovascular
bundle of the neck. The entire bundle was dissected with
trachea and associated muscles, processed, and embedded
in paraplast. Sections of 5 lm were obtained in the region
of carotid bifurcation, and stained with Weigert for elastic
lamellae and thickness evaluations. Histo-morphometric
analyses were performed blinded regarding the identity of
experimental groups (Leica Imaging Systems, Wetzlar, Ger-
many) and analysis were used to measure carotid media
area and elastic lamellae counting (Image Quant-Leica,
Leica Microsystems, Wetzlar, Germany). Internal and
external areas were measured and elastic lamellae were
counted from 5 slices per animal.
Statistical analysis
Data are reported as means  SEM. Student’s t-test was
used to compare the groups. Pearson correlation was used
to determine association among variables. The signifi-
cance level was established as P < 0.05.
Results
Hemodynamics, BRS, and time domain
cardiovascular autonomic modulation
Simvastatin did not significantly alter SAP, diastolic AP
(DAP), or MAP in this model (Table 1). Besides, there
were no differences in time domain AP variability, as
expressed by SAP variance (VAR SAP) between groups.
However, the SHR-S group showed increased HR variabil-
ity, [as] expressed by the PI variance (VAR PI). In addition,
BRS estimated by the response to vasoactive drugs was
higher in the treated group (SHR-S) when compared to the
control (SHR). Indeed, the improvement in BRS was dem-
onstrated by the increase of both reflex tachycardia (ITR)
and reflex bradycardia (IBR) indexes (Table 1).
SAP and HR variability in frequency domain
Table 2 shows the spectral analysis of HR and SAP vari-
ability. Simvastatin significantly reduced sympathetic mod-
ulation of the vessels, represented by the LF component of
SAP. Concerning HR variability, the treatment reduced
sympathetic modulation of the heart, as demonstrated by
ª 2013 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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the reduction of both absolute and normalized power of
the LF component of PI. In addition, simvastatin increased
the normalized HF component of HR variability in treated
animals when compared with untreated SHR, demonstrat-
ing that simvastatin treatment improved vagal modulation
of cardiac autonomic modulation, thus reducing the sym-
pathovagal balance (LF/HF) in the SHR-S group when
compared with SHR group.
Baroreceptor resetting and gain-sensitivity
Simvastatin improved baroreceptor function and sensitiv-
ity, regardless of any changes in AP levels and other
hemodynamic responses in the treated group. SHR-S
presented improved spontaneous aortic nerve activity
response to changes of AP levels at rest as expressed by
the slope of the line relating activity and AP values
(Fig. 1A) and enhanced baroreceptor function, as evalu-
ated by the increase in the percentage of total activity,
which represents the electrical potential outflow of the
aortic depressor nerve (Fig. 1B).
Morphometric analyses of carotid
After treatment with simvastatin, SHR-S presented reduced
external (0.115  0.003 vs. 0.104  0.009 lm, P = 0.035)
and internal (0.134  0.010 vs. 0.101  0.10 lm,
P < 0.001) carotid thickness (Fig. 2A). In addition, we
observed an increase in the number of elastic lamellae in
both external (3.16  0.2 vs. 3.99  0.2 lamellae,
P < 0.001) and internal carotid (3.76  0.36 vs.
4.53  0.36 lamellae, P = 0.003) in the SHR-S group when
compared with control SHR (Fig. 2B). Representative
photomicrographies are presented in Figure 3.
Discussion
The main findings of the present study were that short-
term simvastatin treatment induced an improvement of
cardiovascular autonomic control of the heart and vessels
in SHR, as demonstrated by a reduction in sympathetic
modulation. The mechanisms underlying this reduction
seem to be related to the aortic depressor nerve activity
enhancement. This enhancement would improve BRS and
would lead to better arterial distensibility, as demon-
strated by the increase in the number of carotid elastic
lamellae and the reduction in intima thickness.
Beyond the potent pharmacologic inhibition of choles-
terol biosynthesis of statins, which made this class of
drugs so widely prescribed, their potential pleiotropic
effects – reduction in AP and sympathetic outflow in car-
diovascular disease – have been attracting a growing
interest in recent years (Fisher and Fadel 2010).
Pliquett et al. (2003) were the first to provide evidence
that statin therapy has a potent modulatory effect on
sympathetic tone and autonomic function in an animal
model of chronic heart failure. Furthermore, Kishi et al.
(2003) have observed a significant reduction in 24 h
urinary norepinephrine concentrations in stroke-prone
SHR treated with atorvastatin. More recently, in clinical
settings, studies with chronic kidney disease patients
(Siddiqi et al. 2011) and primary hypertension (Sinski
et al. 2009) have demonstrated a reduction in muscle
sympathetic nerve activity following statin treatment.
The results of the present study are in line with the
experimental and clinical findings. Our study demon-
Table 1. Hemodynamic and autonomic evaluations in awake
spontaneously hypertensive rats (SHR) and SHR-S groups.
SHR SHR-S
SAP (mmHg) 206  3.98 198  1.50
DAP (mmHg) 138  0.60 136  2.91
MAP (mmHg) 170  3.79 165  0.64
HR (bpm) 338  9.65 341  9.02
PI (ms) 176  7.54 178  6.58
VAR SAP (mmHg²) 37.42  4.10 30.20  3.12
VAR PI (ms²) 23.34  3.46 41.62  6.10*
ITR (bpm/mmHg) 0.95  0.11 1.39  0.12*
IBR (bpm/mmHg) 0.67  0.02 1.11  0.13*
Values are mean  SEM. Results of the systolic arterial pressure
(SAP), systolic arterial pressure variance (VARSAP), mean arterial
pressure (MAP), diastolic arterial pressure (DAP), heart rate (HR),
pulse interval (PI), pulse interval variance (VAR PI), index of reflex
tachycardia (ITR), and index of reflex bradycardia (IBR).Student t-
test, *P < 0.05 versus SHR group.
Table 2. Frequency domain analysis of the heart rate and blood
pressure variability in spontaneously hypertensive rats (SHR) and
SHR-S groups.
SHR SHR-S
PI (tachogram)
LF (ms²) 6.84  3.19 2.41  0.96*
LF (NU) 30  3.65 18  1.72*
HF (ms²) 18.39  4.53 16.32  3.07
HF (NU) 70  3.65 82  1.72*
LF/HF 0.45  0.10 0.24  0.02*
SAP(systogram)
LF(z²) 3.95  0.36 2.86  0.18*
Values expressed as mean  SEM. Results of spectral powers of
SAP (systolic arterial pressure) and PI (pulse interval) computed
from 0.20 to 3 Hz (total power plot), low-frequency (LF 0.20–
0.75 Hz) and high-frequency (HF 0.75–3.00 Hz) bands in absolute
(ms2) and normalized units (NU), and autonomic balance (LF/HF) in
SHR and SHR + S groups. Student’s t-test, *P < 0.05 versus SHR
group.
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strated that short-term simvastatin treatment reduced
low-frequency band of PI and of SAP variability in hyper-
tensive rats, leading to/resulting in a considerable
improvement in the sympathovagal balance in treated
animals and thus contributing to a better baroreflex func-
tion. This finding is in accordance with previous studies
which have demonstrated maintenance of blood pressure
and HR values accompanied by changes of autonomic
components to the heart or to the vessels (Kishi et al.
2003; Sinski et al. 2009; Siddiqi et al. 2011).
Oral treatment with simvastatin has been shown to
improve sympathetic outflow and restore arterial barore-
flex function in rabbits with chronic heart failure. This is
probably accomplished by the inhibition of angiotensin II
mechanisms and reactive oxygen species in the rostral
ventrolateral medulla (Pliquett et al. 2003; Gao et al.
2005).
Furthermore, Gao et al. (2008) have offered evidence
that direct intracerebroventricular infusion of simvastatin
has a beneficial effect on sympathetic nerve activity and
baroreflex function in chronic heart failure animals. This
improvement was accompanied by an upregulation of
neuronal NOS protein expression in the rostral ventrolat-
eral medulla.
Similarly, Kishi et al. (2003) have demonstrated that a
30-day atorvastatin treatment in hypertensive rats led to
an upregulation of brainstem eNOS and significant reduc-
tions in urinary noradrenaline excretion and AP. Further-
more, the oral administration of atorvastatin inhibited the
activation of the sympathetic nervous system and
improved the baroreflex control in hypertensive rats via
reduction in reactive oxygen species in the rostral ventro-
lateral medulla of hypertensive rats (Kishi et al. 2008,
2009). In mice with sympathetic hyperactivity induced by
myocardial infarction, the increase in eNOS expression in
the nucleus tractus solitarius significantly attenuated the
enhanced sympathetic drive (Sakai et al. 2005).
In order to expand our knowledge about the mecha-
nisms underlying the reduction in sympathetic nervous
activity in hypertension condition, we also hypothesized
that an alteration in loco might influence the sensitivity
and function of baroreceptors, the most important
short-term control mechanism of AP regulation altered
by hypertension. Indeed, the loss of distensibility of the
SHR-S
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Figure 1. Baroreflex function and sensitivity. (A) Spontaneous aortic depressor nerve activity, expressed by% of maximal activity/mmHg in
spontaneously hypertensive rats (SHR) and SHR-S; (B) Representative experiment of baroreceptor function curve showing the changes in aortic
activity (top) associated with pulse pressure variation induced by vasoactive drug infusion. (C) Baroreceptor function curve obtained by the
aortic activity changes related to induced variations of arterial pressure. (D) Slope of the baroreceptor function curve expressed by%maximal
activity/mmHg in SHR and SHR-S, obtained by arterial pressure (AP)-induced changes. Values expressed as mean  SEM, (A): Pearson
Correlation, (B) Student t-test, *P < 0.05 versus SHR group.
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aorta and carotid arteries has been associated with
changes in BRS (Hunt et al. 2001; Kaushal and Taylor
2002), as the mechanical stress of the arteries wall
would not be able to adequately trigger the mechanore-
ceptors.
It is worth stressing that most of the studies on the
pleiotropic effects of statins, reported AP reduction after
treatment. In our study, we chose a simvastatin dose
(5 mg/kg/day) which would not induce AP alteration in
SHR, in an attempt to isolate the observed responses
from the hemodynamic effect, as an AP decrease is by
itself a contributor to functional and structural beneficial
adaptations. Therefore, we observed that, even with unal-
tered AP, simvastatin increased the number of elastic
lamellae and decreased intima thickness in the internal
and external carotid in SHR.
In this sense, the mechanism associated with a reduc-
tion in sympathetic modulation of the heart and vessels
by simvastatin treatment may also be associated with
positive morphological changes in carotid and may be
further extended to other vessels, as the aorta, improving
artery mechanical distension, and triggering more effi-
ciently the baroreflex signal to the nucleus of the solitary
tract in the bulb. In this way, the central sympathetic
response to the heart and peripheral vasculature would be
reduced. However, a question that needs to be answered
concerns the underlying mechanisms of improved vascu-
lar remodeling by simvastatin treatment.
It has been demonstrated that atorvastatin reduced the
collagen content and improved the alterations of elastin
structure induced by angiotensin II in resistance arteries
of rats (Briones et al. 2009). Indeed, statins can directly
induce eNOS by activating phosphatidylinositol-3-kinase
(PI3K)/protein kinase B/Akt signals (Kureishi et al. 2000)
that inhibit the Rho A/Rho kinase signaling and upregu-
late eNOS expression (Rikitake and Liao 2005; Balakumar
et al. 2012). In addition, statins abrogate caveolin-1
expression, which is a negative eNOS regulator (Plenz
et al. 2004; Balakumar et al. 2012).
In large arteries, statin treatment decreased perivascular
coronary artery fibrosis (Kishi et al. 2008), oxidative stress
in the aorta (Zhou et al. 2004), and extracellular matrix
deposition in the heart (Zhai et al. 2008) and rat aorta
(Ruperez et al. 2007). In fact, a recent meta-analysis
involving 6317 individuals has demonstrated that statin
therapy was efficient in reducing common carotid intima-
media thickness (Balakumar et al. 2012). Furthermore,
Ratchford et al. (Plenz et al. 2004) have observed
decreased stiffness and increased distensibility in carotids
of humans after a 30-day atorvastatin treatment, regard-
less of cholesterol lowering.
On the other hand, we cannot rule out the hypothesis
that a central action of simvastatin reduced efferent sym-
pathetic discharge (as evaluated by LF component of the
heart and vessels), modulating oxidative stress, inflamma-
tion, and, consequently structural changes in carotid
artery. In fact, the increase in AP variability, without any
changes in AP levels, triggered negative morphological
changes in left and right ventricles (Moraes-Silva et al.
2010; Flues et al. 2012), as well as in the vessels (Ceroni
et al. 2009) of sinoaortic denervated animals. Addition-
ally, previous studies have demonstrated that autonomic
nervous system can modulate inflammation and oxidative
stress (Pavlov and Tracey 2012). Recently, in a study
involving simvastatin treatment associated or not with
exercise training, we have observed that the cardiac
lipoperoxidation was negatively related to the vagal effect,
and positively correlated to the sympathetic effect
(Bernardes et al. 2013).
In this sense, the reduction of sympathetic compo-
nent (LF band) to the heart and vessels may reduce
inflammation and oxidative stress, reducing carotid his-
topathological changes, and as such improving barore-
flex afference. In other words, regardless of the
mechanisms involved in arterial structural changes, the
increase in baroreceptor afferent discharge in treated
animals may account for the reduced peripheral sympa-
thetic modulation.
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Figure 2. External and Internal carotid morphology. (A) Medial
external and internal carotid thickness. (B) Number of elastic
lamellae in external and internal carotid. Student t-test, *P < 0.05
versus spontaneously hypertensive rats (SHR).
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In summary, the data of the present investigation
suggest that short-term simvastatin treatment induce
improvement in PI variability, reduction in sympathetic
modulation of the heart and vessels, as well as increase
in BRS in SHR, regardless of changes in the AP. The
possible mechanism associated with this autonomic
improvement was a structural change in the carotid
arteries, leading to an adequate trigger of the mechano-
receptors and an improved afferent pathway of the
baroreflex arch. Although clinical trials are required to
determine whether carotid evaluation may predict car-
diovascular autonomic control, and whether these pleio-
tropic effects of statins may prevent cardiovascular
outcomes, this study lends support to the possible asso-
ciation of arterial morphology to estimate BRS and
function, and sympathetic outflow in hypertensive sub-
jects.
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